Live tape
Top 8, mentions 7d10,861GOOGL2,073 mentions▲ +0.04SNDK1,532 mentions▲ +0.11SPCX1,499 mentions▲ +0.08NBIS1,427 mentions▲ +0.10HTZ1,236 mentions▲ +0.10NVDA1,205 mentions▲ +0.08META1,045 mentions▲ +0.03MSFT844 mentions▲ +0.06

Equity · Healthcare

MDGL

Madrigal Pharmaceuticals, Inc. · NasdaqGS

$514 +1.18% 1D Finazon · prior-day close · Aug 5, 2026
Price · Chart
Our own end-of-day closes 53 sessions
$600 $450 20 May 5 Aug

The line runs $513 on 20 May through $514 on 5 August, on a scale from $450 to $600. Days the market did not trade hold the previous close, flat.

Track this symbol on TradingView

The chart above plots the price of MDGL over the range selected — one day to the full history — drawn by TradingView from their own data. Our own licensed end-of-day series holds 53 sessions over that window: $513 on 20 May 2026 through $514 on 5 August 2026.

Market cap $11.9B
52-week range $289 – $604
Avg volume 117.0K

Finazon · prior-day close · valuation computed from SEC EDGAR filings · as of Aug 18, 2026

MDGL insider trades

SEC Form 4 · last 90 days · newest reported trade 20 Jul 2026
Open-market buys 0
Open-market sells 3
Net sold $4.79M
Non-trade filings 6
Date Insider Type Shares Value
20 Jul 2026 Sibold William John President and CEO Sell 2,500 $1.37M
01 Jun 2026 Soergel David Chief Medical Officer Sell 1,042 $517K
22 May 2026 Levy Richard S Director Sell 5,642 $2.91M

Compensation mechanics Share grants, option exercises, tax withholding and transfers. They reach the same Form 4 as a trade, but they are not the insider buying or selling on the open market, so no purchase or sale value applies to them.

Date Insider Type Shares Value
17 Jul 2026 Sibold William John President and CEO Option exercise 50,000
17 Jun 2026 Brennan Daniel J. Director Award 404
17 Jun 2026 Daly James M Director Award 454
17 Jun 2026 FOUSE JACQUALYN A Director Award 454
17 Jun 2026 Levy Richard S Director Award 454
17 Jun 2026 Taub Rebecca Director Award 454

MDGL reported financials

SEC EDGAR XBRL

MDGL reported revenue of $958.4M for the fiscal year ended 31 Dec 2025. Net income over the same period was −$288.3M.

Figure Reported Period
Revenue $958.4M 31 Dec 2025 fiscal year
Net income −$288.3M 31 Dec 2025 fiscal year
Diluted EPS −$10.15 31 Dec 2025 fiscal year
Total assets $1.2B 30 Jun 2026 at period end
Total equity $523.7M 30 Jun 2026 at period end

Source: SEC EDGAR XBRL company facts · latest period ended 30 Jun 2026

MDGL earnings

SEC EDGAR
Date Period EPS Revenue
30 Jun 2026 Q2 2026 $-1.99 —
31 Mar 2026 Q1 2026 $-3.25 —
31 Dec 2025 Q2 2026 $-10.15 —
30 Sep 2025 Q2 2026 $-4.01 —
30 Jun 2025 Q1 2026 $-1.50 —
31 Mar 2025 Q1 2025 $-2.61 $137M

Next report no date announced in SEC filings yet

Reported figures & scheduled dates · SEC EDGAR filings

MDGL institutional holders

SEC Form 13F

11 of the 45 institutional funds we track reported a MDGL position for the quarter ended 30 Jun 2026 — a combined $1.7B; the latest of those filings landed 14 Aug 2026.

Fund Action Shares Value
Baker Bros. Advisors Held (±25%) +0.1% shares 2,143,131 $1.2B
Citadel Advisors Held (±25%) +11.8% shares 507,233 $272.4M
Point72 Asset Management Trimmed −39.2% shares 137,029 $73.6M
Marshall Wace Added +365.1% shares 101,859 $54.7M
Millennium Management Added +98.8% shares 81,196 $43.6M
Balyasny Asset Management New position 79,011 $42.4M
Renaissance Technologies Trimmed −36.1% shares 45,942 $24.7M
D. E. Shaw & Co. Held (±25%) +16.4% shares 35,071 $18.8M
AQR Capital Management Held (±25%) −0.8% shares 15,827 $8.5M
Tudor Investment Corp Held (±25%) −1.0% shares 11,509 $6.2M

Showing the 10 largest of 11 reported positions. The figures above count all of them.

Source: SEC EDGAR 13F filings

MDGL fails-to-deliver

SEC CNS data

On 27 Jul 2026, 143 shares of MDGL failed to deliver (about $78K).

Settlement date Shares failed Notional % of shares out
27 Jul 2026 143 $78K 0.001%
20 Jul 2026 49 $27K <0.001%
10 Jul 2026 6,215 $3.5M 0.027%
08 Jul 2026 1,670 $911K 0.007%

Source: SEC fails-to-deliver (CNS) data